Vein-to-vein time and manufacturing slots
For CAR-T, the number of days from collecting the patient's cells to infusing the finished product, typically three to six weeks. Every day counts when the disease is aggressive, and manufacturing capacity (slots) limits how many patients can be treated.
Vein-to-vein time includes shipping, manufacturing (transduction, expansion, release testing), cryopreservation and scheduling; commercial products average 3-4 weeks in the US and longer in Europe. Delays force bridging therapy and cost lives, which is the motivation for rapid manufacturing platforms (T-Charge, 2-day processes), point-of-care and closed automated manufacturing, in vivo CAR-T and allogeneic products. Slots are allocated per centre and per month, out-of-specification products may still be infused under expanded access, and chain-of-identity software tracks each patient's cells. In ZUMA-7 the median vein-to-vein time of about 4 weeks versus 52 days in another trial was cited as a reason for different outcomes.
Pages like this
not linked directly; found by shared links- CompanyCellares
Shares Point-of-care and decentralised cell manufacturing, Closed automated cell-therapy manufacturing.
- CompanyMiltenyi Biotec
Shares Point-of-care and decentralised cell manufacturing, Closed automated cell-therapy manufacturing.
- TechnologyCryopreservation and cell-therapy cold chain
Shares Cell-therapy orchestration and chain-of-identity software, CAR-T cell therapy.
- TechnologyCell-therapy release and potency testing
Shares Closed automated cell-therapy manufacturing, CAR-T cell therapy.
- TechnologyApheresis and starting-material collection
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares Point-of-care and decentralised cell manufacturing, CAR-T cell therapy.
- InstitutionAdvanced Centre for Treatment, Research and Education in Cancer
Shares Point-of-care and decentralised cell manufacturing, CAR-T cell therapy.
- TrialZUMA-7
Shares Bridging therapy, CAR-T cell therapy.